Latest & greatest articles for heparin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heparin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heparin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heparin

161. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety

Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness (...) and safety CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus unfractionated heparin for thromboprophylaxis in surgery, cancer and general medicine: a review of the cost-effectiveness and safety. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). Rapid Response - Summary

2014 Health Technology Assessment (HTA) Database.

162. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness

Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT (...) and PE: a review of the clinical and cost-effectiveness CADTH Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation CADTH. Low molecular weight heparins versus new oral anticoagulants for long-term thrombosis prophylaxis and long-term treatment of DVT and PE: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs

2014 Health Technology Assessment (HTA) Database.

163. The efficacy and safety of low-molecular weight heparins in critically ill patients: a systematic review and meta-analysis

The efficacy and safety of low-molecular weight heparins in critically ill patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence

2014 PROSPERO

164. Bivalirudin versus heparin during percutaneous intervention: a systematic review and meta-analysis

Bivalirudin versus heparin during percutaneous intervention: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2014 PROSPERO

165. Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. (Abstract)

Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial. Bivalirudin, with selective use of glycoprotein (GP) IIb/IIIa inhibitor agents, is an accepted standard of care in primary percutaneous coronary intervention (PPCI). We aimed to compare antithrombotic therapy with bivalirudin or unfractionated heparin during this procedure.In our open-label, randomised controlled trial, we enrolled (...) consecutive adults scheduled for angiography in the context of a PPCI presentation at Liverpool Heart and Chest Hospital (Liverpool, UK) with a strategy of delayed consent. Before angiography, we randomly allocated patients (1:1; stratified by age [<75 years vs ≥75 years] and presence of cardiogenic shock [yes vs no]) to heparin (70 U/kg) or bivalirudin (bolus 0·75 mg/kg; infusion 1·75 mg/kg per h). Patients were followed up for 28 days. The primary efficacy outcome was a composite of all-cause mortality

2014 Lancet Controlled trial quality: predicted high

166. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati (Abstract)

Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, stratum-specific likelihood rati Heparin-induced thrombocytopenia (HIT) is diagnosed using clinical criteria and detection of platelet-activating anti-platelet factor 4/heparin (anti-PF4/H) antibodies, usually through a surrogate enzyme-linked immunosorbent assay (ELISA

2014 EvidenceUpdates

167. Citrate Versus Heparin Lock for Hemodialysis Catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials (Abstract)

Citrate Versus Heparin Lock for Hemodialysis Catheters: A Systematic Review and Meta-analysis of Randomized Controlled Trials Citrate solution has been suggested as an effective and safe catheter lock in hemodialysis. However, whether a citrate lock is superior to a heparin lock in preventing catheter-related infections and maintaining catheter patency is inconclusive.A systematic review and meta-analysis was performed by searching in PubMed, EMBASE, Ovid, the Cochrane Library, and Web (...) of Science databases and major nephrology journals.Patients receiving hemodialysis with central venous catheters.Randomized controlled trials comparing citrate locks with heparin locks in hemodialysis patients with central venous catheters.Locking central venous catheters with citrate locks.Primary outcomes include catheter-related bloodstream infection (CRBSI), exit-site infection, catheter removal for poor flow, and thrombolytic treatment.13 randomized controlled trials (1,770 patients, 221,064

2014 EvidenceUpdates

168. Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup Full Text available with Trip Pro

Heparin-bonded covered stents versus bare-metal stents for complex femoropopliteal artery lesions: the randomized VIASTAR trial (Viabahn endoprosthesis with PROPATEN bioactive surface [VIA] versus bare nitinol stent in the treatment of long lesions in sup The hypothesis that endovascular treatment with covered stents has equal risks but higher efficacy than bare-metal stents (BMS) in long femoropopliteal artery disease was tested.Although endovascular treatment of short superficial femoral (...) artery lesions revealed excellent results, efficacy in long lesions remains unsatisfactory.In a prospective, randomized, single-blind, multicenter study, 141 patients with symptomatic peripheral arterial disease were assigned to treatment with heparin-bonded, covered stents (Viabahn 72 patients) or BMS (69 patients). Clinical outcomes and patency rates were assessed at 1, 6, and 12 months.Mean ± SD lesion length was 19.0 ± 6.3 cm in the Viabahn group and 17.3 ± 6.6 cm in the BMS group. Major

2013 EvidenceUpdates Controlled trial quality: predicted high

169. Heparin for assisted reproduction. Full Text available with Trip Pro

Heparin for assisted reproduction. Heparin as an adjunct in assisted reproduction (peri-implantation heparin) is given at or after egg collection or at embryo transfer during assisted reproduction. Heparin has been advocated to improve embryo implantation and clinical outcomes.  It has been proposed that heparin enhances the intra-uterine environment by improving decidualisation with an associated activation of growth factors and a cytokine expression profile in the endometrium (...) that is favourable to pregnancy.To investigate whether the administration of heparin around the time of implantation (peri-implantation heparin) improves clinical outcomes in subfertile women undergoing assisted reproduction.A comprehensive and exhaustive search strategy was developed in consultation with the Trials Search Co-ordinator of the Cochrane Menstrual Disorders and Subfertility Group (MDSG). The strategy was used in an attempt to identify all relevant studies regardless of language or publication

2013 Cochrane

170. Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety

Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety TITLE: Low Molecular Weight Heparins Versus Unfractionated Heparin for Thromboprophylaxis in Surgery, Cancer and General Medicine: A Review of the Cost-effectiveness and Safety DATE: 02 July 2013 CONTEXT AND POLICY ISSUES Low molecular weight heparins (LMWH) have emerged as an important alternative to unfractionated heparin (...) . LMWH are at least as effective antithrombotic drugs as UFH, however, it is still unclear whether the safety profiles of LMWH and UFH differ. 12 The important adverse events of heparin includes heparin-induced thrombocytopenia (HIT), an adverse drug reaction presenting as a prothrombotic disorder related to antibody-mediated platelet activation, 13 and bleeding. In 2009, CADTH published a review on the cost-effectiveness of LMWH compared with UFH. 11 It was reported in that review that LMWH appeared

2013 Canadian Agency for Drugs and Technologies in Health - Rapid Review

171. Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. Full Text available with Trip Pro

Once versus twice daily low molecular weight heparin for the initial treatment of venous thromboembolism. In the initial treatment of venous thromboembolism (VTE) low molecular weight heparin (LMWH) is administered once or twice daily. A once daily treatment regimen is more convenient for the patient and may optimise home treatment. However, it is not clear whether a once daily treatment regimen is as safe and effective as a twice daily treatment regimen. This is the second update of a review

2013 Cochrane

172. Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. (Abstract)

Low molecular weight heparin for prevention of microvascular occlusion in digital replantation. The success of digital replantation is highly dependent on the patency of the repaired vessels after microvascular anastomosis. Antithrombotic agents are frequently used for preventing vascular occlusion. Low molecular weight heparin (LMWH) has been reported to be as effective as unfractionated heparin (UFH) in peripheral vascular surgery, but with fewer adverse effects. Its benefit in microvascular

2013 Cochrane

173. Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. (Abstract)

Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease. Sickle cell disease is one of the most common and severe genetic disorders in the world. It can be broadly divided into two distinct clinical phenotypes characterized by either haemolysis or vaso-occlusion. Pain is the most prominent symptom of vaso-occlusion, and hypercoagulability is a well-established pathogenic phenomenon in people with sickle cell disease. Low-molecular-weight heparins (...) might control this hypercoagulable state through their anticoagulant effect.To assess the effects of low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Haemoglobinopathies Trials Register comprising references identified from comprehensive electronic database searches. We also searched abstract books of conference proceedings and several online trials registries for ongoing

2013 Cochrane

174. Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial

Heparin-bonded central venous catheters do not reduce thrombosis in infants with congenital heart disease: a blinded randomized, controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2013 PedsCCM Evidence-Based Journal Club

175. Low-Dose Heparin Use and the Patency of Peripheral IV Catheters in Children: A Systematic Review Full Text available with Trip Pro

Low-Dose Heparin Use and the Patency of Peripheral IV Catheters in Children: A Systematic Review To assess evidence from randomized controlled trials (RCTs) on the efficacy of low-dose heparin for prolonging patency of peripheral intravenous (PIV) catheters in the pediatric population.We searched Medline, Embase, CINAHL, and Cochrane Central Register of Controlled Trials to identify studies up to June 6, 2012. Additional citations were retrieved from the bibliography of selected articles (...) . The eligible studies were RCTs of low-dose heparin used in PIV catheters as compared with control and measured any one of the following outcomes: duration of catheter patency, infusion failure rates, or phlebitis. Data were extracted by 1 reviewer by using a standardized form and checked for accuracy by a second reviewer. Discrepancies were resolved by consensus.Thirteen RCTs were identified (3 RCTs of continuous infusion and 10 RCTs of intermittent flush). Catheters using heparin had longer patency (mean

2013 EvidenceUpdates

176. Methods for administering subcutaneous heparin during pregnancy. (Abstract)

Methods for administering subcutaneous heparin during pregnancy. Pregnant women with a history of venous thromboembolism (VTE), antithrombin deficiency, or other risk factors for VTE, need heparin (unfractionated heparin (UFH) or low-molecular weight heparin (LMWH)) prophylaxis, mainly through administering subcutaneously. Several methods of administering heparin (UFH or LMWH) subcutaneously have been introduced to prevent adverse pregnant outcomes. The effectiveness and safety of different (...) methods administering subcutaneous heparin (UFH or LMWH) during pregnancy have not been systematically evaluated.To compare the effectiveness and safety of different methods of administering subcutaneous heparin (UFH or LMWH) to pregnant women.We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 January 2013) and reference lists of retrieved studies.All randomised controlled trials (individual and cluster) comparing the effectiveness and safety of different methods

2013 Cochrane

177. Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial

Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic stroke: a hospital perspective of the PREVAIL trial Economic impact of enoxaparin versus unfractionated heparin for venous thromboembolism prophylaxis in patients with acute ischemic (...) unfractionated heparin, to prevent venous thromboembolism, after an acute ischaemic stroke. The authors concluded that the higher cost of enoxaparin was offset by fewer clinical events, compared with unfractionated heparin, particularly for patients with more severe stroke. The study focused on the economic data and was satisfactorily carried out. The authors’ conclusions appear to be robust. Type of economic evaluation Cost-effectiveness analysis Study objective This study examined the clinical and economic

2013 NHS Economic Evaluation Database.

178. Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Full Text available with Trip Pro

Intravitreal low molecular weight heparin and 5-Fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Proliferative vitreoretinopathy (PVR) is a significant cause of failure in retinal reattachment surgery. Various pharmacological agents have shown potential benefit in reducing postoperative PVR risk.This review aimed to compare the use of intravitreal low molecular weight heparin (LMWH) alone or with 5-Fluorouracil (5-FU) versus placebo

2013 Cochrane

179. Use of heparins in cancer: individual patient data meta-analysis

Use of heparins in cancer: individual patient data meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures

2013 PROSPERO

180. Immunological testing for the diagnosis of heparin-induced thrombocytopenia: impact of optical density cut-off on sensitivity and specificity

Immunological testing for the diagnosis of heparin-induced thrombocytopenia: impact of optical density cut-off on sensitivity and specificity Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2013 PROSPERO